June 27, 2017

Willkie represents biopharmaceutical company Clovis Oncology, Inc. in its underwritten public offering of $345 million of shares of its common stock.

Willkie client Clovis Oncology, Inc. (NASDAQ:CLVS) recently announced an underwritten public offering of 3,409,091 shares of its common stock at $88.00 per share. The offering was upsized from $250 million to $300 million. In addition, the underwriters have exercised their full option to purchase an additional 511,363 shares, bringing the total value of the offering to $345 million. The offering closed on June 26.

J. P. Morgan Securities LLC and BofA Merrill Lynch acted as joint book-running managers for the offering, and Stifel and SunTrust Robinson Humphrey acted as co-managers.

Based in Boulder, CO, Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets.

The transaction was handled by partner Thomas Mark and associates Ted Powers and Neesha Mallavarapu.

Thomas Mark
Thomas Mark Partner Corporate & Financial Services